X

Drug Profile

AMT 260

Alternative Names: AAV9-hSyn1-miGRIK2; AMT-260

Latest Information Update: 08 Aug 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Corlieve Therapeutics
Class Antiepileptic drugs; Gene therapies; MicroRNAs
Mechanism of Action Kainic acid receptor antagonists; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Temporal-lobe-epilepsy

Most Recent Events

07 May 2024 uniQure plans a phase I/IIa trial in Temporal lobe epilepsy (Treatment-experienced) in USA in the third quarter of 2024 (NCT06063850)
28 Feb 2024 UniQure has patents pending entitled "Methods and compositions for treating epilepsy" in Israel, Australia and Canada
05 Sep 2023 US FDA approves IND application for AMT 260 in Temporal lobe epilepsy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com